Key facts
- This page summarizes David I. Rosenberg's Form 4 filing for Peak Bio, Inc..
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Nov 2022, 21:52.
David I. Rosenberg - 01 Nov 2022 Form 4 Insider Report for Peak Bio, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Nov 2022
- Net transaction value
- +$2,500,000
- Reporting owner signature
- /s/ David I. Rosenberg
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
David I. Rosenberg filed Form 4 for Peak Bio, Inc. on 03 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$2,500,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PKBO
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,437,500
- Change %
- Price
- $0.000000
- Shares after
- 1,437,500
- Date
- 01 Nov 2022
- Ownership
- See Footnote
- Footnotes
- F2
PKBO
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +77,200
- Change %
- +5.4%
- Price
- $0.000000
- Shares after
- 1,514,700
- Date
- 01 Nov 2022
- Ownership
- See Footnote
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PKBO
transaction
Derivative
Class F Common Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,437,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Nov 2022
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 1,437,500
- Exercise price
- Footnotes
- F1, F2
PKBO
transaction
Derivative
Private Placement Warrants
Award
- Transaction value
- $2,500,000
- Shares
- +2,500,000
- Change %
- Price
- $1.00
- Shares after
- 2,500,000
- Date
- 01 Nov 2022
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,500,000
- Exercise price
- $11.50
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On November 1, 2022, Ignyte Acquisition Corp. ("Ignyte" and the former name of the Issuer) consummated its initial business combination (the "Business Combination") with Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea. In connection with the consummation of the Business Combination, each share of Class F common stock, par value $0.0001 per share, of Ignyte automatically converted into one share of Class A common stock, par value $0.0001 per share, of the Issuer.
Footnote F2
These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein.
Footnote F3
The private placement warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934 concurrent with the closing of the Business Combination (the "Closing"), because, pursuant to their terms, their exercise was not within the control of the Reporting Person until the Closing. Each private placement warrant is exercisable for one share of the Issuer's Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants may be exercised commencing 30 days after the Closing and expire five years after the Closing or earlier upon redemption or liquidation. The private placement warrants consist of 2,500,000 private placement warrants purchased by the Sponsor in a private placement from Ignyte simultaneously with the consummation of Ignyte's initial public offering.
Footnote F4
Pursuant to a Payment Agreement between Ignyte and the Sposnor entered into connection with the Business Combination, the Sponsor received these securities in a private placement in lieu of the aggregate principal amount of working capital loans owed to the Sponsor by Ignyte.
SEC remarks
Exhibit 24 - Power of Attorney